HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Finn, A Articles by Heath, P Search for Related Content PubMed PubMed Citation Articles by Finn, A Articles by Heath, P Topic Collections Relevant Article

Should the new pneumococcal vaccine be used in high-risk children?

¹ Institute of Child Health, University of Bristol, UK
² St George's Vaccine Institute and St George's Hospital Medical School, Tooting, London, UK
³ Royal London Hospital, Whitechapel, London, UK
⁴ Oxford Vaccine Group, Oxford, UK

Correspondence to:
Correspondence to:
Prof. A Finn, Institute of Child Health, UBHT Education Centre, Level 6, Upper Maudlin St, Bristol BS2 8AE, UK;
Adam.Finn{at}bristol.ac.uk

ABSTRACT
A new conjugate 7-valent vaccine to prevent pneumococcal infection (Prevenar, Wyeth) has recently received a European licence for use in young healthy children. The vaccine is not currently included in the universal immunisation schedule in the UK or elsewhere in Europe, although it is being used widely in the USA. Its availability for purchase raises the question whether paediatricians should consider using it in high risk children, including those for whom the polysaccharide 23-valent vaccine was previously recommended, until (or unless) it is introduced into general use—indeed the Chief Medical Officer for England and Wales has recently made a recommendation regarding such children aged less than 2 years. We review the evidence concerning use of the vaccine in such children and make suggestions as to how the vaccine may be used while further information is collected.

Keywords: pneumococcal vaccine; Prevenar

Abbreviations: AAP, American Academy of Paediatrics; CSF, cerebrospinal fluid; SCD, sickle cell disease

Relevant Article

KEEPING IT CLEAN

Harvey Marcovitch
Arch. Dis. Child. 2002 87: 1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				K M Eastham, R Freeman, A M Kearns, G Eltringham, J Clark, J Leeming, and D A Spencer Clinical features, aetiology and outcome of empyema in children in the north east of England Thorax, June 1, 2004; 59(6): 522 - 525. [Abstract] [Full Text] [PDF]

				E D G McIntosh How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine? Arch. Dis. Child., October 1, 2003; 88(10): 859 - 861. [Abstract] [Full Text] [PDF]

				R Lakshman, A R Gennery, P D Arkwright, T Flood, M Abinun, G Spickett, R Borrows, A J Cant, P Balmer, and R Borrow Assessing immune responses to pneumococcal vaccines Arch. Dis. Child., July 1, 2003; 88(7): 648 - 649. [Full Text] [PDF]

				S Thayyil, V N Murthy, and F Thompson Sudden infant death due to disseminated pneumococcal infection Arch. Dis. Child., February 1, 2003; 88(2): 157 - 157. [Full Text] [PDF]

				A Finn, R Booy, M Sharland, and P Heath Conflicting advice Arch. Dis. Child., February 1, 2003; 88(2): 176 - 176. [Full Text] [PDF]

eLetters: